STI acquisition rates did not differ in HIV-infected DMPA users and nonusers.
Effective contraception is particularly important for HIV-infected women who do not want to have children. Previous studies suggested that use of depot medroxyprogesterone acetate (DMPA), although highly effective at preventing pregnancies, might be associated with increased risk for acquiring sexually transmitted infections (STIs). To assess whether STI transmission risk varies with contraceptive method, investigators identified incident cases of gonorrhea, chlamydia, and trichomoniasis among 304 HIV-seropositive women who were seen at a university outpatient clinic.
In this retrospective cohort, 82 women received DMPA and 222 did not. At a mean follow-up of 2.8 years, rates of trichomoniasis (overall, 8.4 per 100 person-years), chlamydia (…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)